Exclusive: Arbutus Biopharma Corp Has Another Very Weak Trading Session

Exclusive: Arbutus Biopharma Corp Has Another Very Weak Trading Session

The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) is a huge mover today! The stock decreased 11.57% or $0.45 during the last trading session, hitting $3.44. About 860,300 shares traded hands or 745.15% up from the average. Arbutus Biopharma Corp (NASDAQ:ABUS) has risen 25.89% since February 26, 2016 and is uptrending. It has outperformed by 15.47% the S&P500.
The move comes after 7 months negative chart setup for the $192.97 million company. It was reported on Oct, 1 by Barchart.com. We have $2.99 PT which if reached, will make NASDAQ:ABUS worth $25.09 million less.

Analysts await Arbutus Biopharma Corp (NASDAQ:ABUS) to report earnings on November, 3. They expect $-0.57 EPS, down 35.71% or $0.15 from last year’s $-0.42 per share. After $-0.35 actual EPS reported by Arbutus Biopharma Corp for the previous quarter, Wall Street now forecasts 62.86% negative EPS growth.

Arbutus Biopharma Corp (NASDAQ:ABUS) Ratings Coverage

Out of 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. Arbutus Biopharma has been the topic of 9 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by RBC Capital Markets given on Friday, November 6. The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) has “Outperform” rating given on Friday, August 7 by Wedbush. Wedbush initiated it with “Outperform” rating and $20.0 target price in Friday, August 7 report. Chardan Capital Markets downgraded it to “Sell” rating and $2.75 target price in Friday, July 8 report. The rating was upgraded by Chardan Capital Markets on Thursday, June 16 to “Neutral”. The firm has “Market Perform” rating given on Friday, August 5 by Leerink Swann. Chardan Capital Markets initiated the stock with “Sell” rating in Monday, May 16 report. The rating was initiated by JMP Securities with “Mkt Outperform” on Wednesday, September 2.

According to Zacks Investment Research, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.”

More important recent Arbutus Biopharma Corp (NASDAQ:ABUS) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on December 29, 2013, also Streetinsider.com published article titled: “Arbutus Biopharma (ABUS) Announces Results from Phase II Trial of ARB-1467 for …”, Globenewswire.com published: “Tekmira Announces Launch of Arbutus Biopharma, a Hepatitis B Solutions Company” on July 20, 2015. More interesting news about Arbutus Biopharma Corp (NASDAQ:ABUS) was released by: Quotes.Wsj.com and their article: “News Arbutus Biopharma Corp.ABUS” with publication date: August 06, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment